Boehringer In­gel­heim en­lists a UK start­up in a mile­stone-heavy quest for 'dark anti­gen­s'

A year af­ter rais­ing $17.5 mil­lion for a plat­form to search for so-called “dark anti­gens” lurk­ing in tu­mors, Enara Bio has nabbed a buy­er for at least some of what that plat­form found.

Enara an­nounced Tues­day a part­ner­ship with Boehringer In­gel­heim, where­by the Ger­man big phar­ma would de­vel­op can­cer vac­cines and bis­pe­cif­ic an­ti­bod­ies tar­get­ed at Enara-dis­cov­ered anti­gens in lung or GI can­cers. Up­front terms weren’t dis­closed but Enara will be el­i­gi­ble to earn as much as $960 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER